drugset

drugset / Trial / NCT03669640

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640 ↗

Phase 2 Terminated 131 enrolled Hoffmann-La Roche

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Timeline

Start: 2018-12-04
Primary completion: 2023-03-12
Completion: 2023-03-12

Publications

Halff EF, Rutigliano G, Garcia-Hidalgo A, Howes OD. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. doi: 10.1016/j.tins.2022.10.010. Epub 2022 Nov 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ralmitaront	Small molecule	—	Oral

Indications